We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Companies wager high on CD38-targeting drugs for blood cancer.
- Authors
Hersher, Rebecca
- Abstract
The article informs that GenMab A/S has signed a 1.1 billion U.S. dollars contract for licensing rights for its blood cancer drug daratumumab with Janssen Biotech Inc., a subsidiary of the company Johnson & Johnson. It informs that the drug developers have an emerging class of medicines which are designed for treating blood cancers. It mentions that the treatment for blood cancers rely on disruption of the tumor environment by the restriction of blood flow.
- Subjects
GENMAB A/S; JANSSEN Biotech Inc.; CONTRACTS; BLOOD-vessel tumors; JOHNSON &; Johnson (Company); TUMOR treatment
- Publication
Nature Medicine, 2012, Vol 18, Issue 10, p1446
- ISSN
1078-8956
- Publication type
Article
- DOI
10.1038/nm1012-1446a